Gland Pharma advanced 5.88% to Rs 1,858.40 after it received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
Gland Pharma advanced 5.88% to Rs 1,858.40 after it received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection.
| Subscribe To Our Free Newsletter |
